# US 2016/0250345 A1 · Pyrrolobenzodiazepines and conjugates thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250345 A1
- Document ID: US20160250345A1
- Status: Published application
- Kind: A1
- Application number: 15/028,580
- Filed: 2014-10-10
- Published: 2016-09-01
- Earliest claimed: 2013-10-11
- Assignees: MedImmune, LLC
- Applicants: Medimmune Limited
- Inventors: Philip Wilson Howard; Ebele Ezeadi; Francois D'Hooge; Neki Patel; Gary Kemp
- Web page: https://patentgrep.com/patent/US20160250345A1

## CPC

- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/68035: {the drug being a pyrrolobenzodiazepine}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61P 35/00: Antineoplastic agents
- C07D 487/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A compound which is selected from A: A O OO O O O I O NH O O O O O O O O N H N H N H OO OH H O N N OO H N N B: 5 B O OO O O O Br O NH O O O O O O O O N H N H N H OO OH H O N N OO H N N; and C C O O N H N H O N H OO OO O O N O OO O O O O NH O O O O O O O O N H N H N H OO OH H O N N OO OH H N N; and salts and solvates thereof.

## Claims

### Claim 1

A compound which is
and salts and solvates thereof.

### Claim 2

A conjugate of formula
ConjC:
where CBA represents a cell binding agent.

### Claim 3 (depends on 2)

The conjugate according to claim 2, wherein the cell binding agent is an antibody or an active fragment thereof.

### Claim 4 (depends on 3)

The conjugate according to claim 3, wherein the antibody or antibody fragment is an antibody or antibody fragment for a tumour-associated antigen.

### Claim 5 (depends on 3)

The conjugate of claim 3 wherein the antibody or antibody fragment is an antibody which binds to one or more tumor-associated antigens or cell-surface receptors selected from (1)-(88):
(1) BMPR1B;
(2) E16;
(3) STEAP1;
(4) 0772P;
(5) MPF;
(6) Napi3b;
(7) Sema 5b;
(8) PSCA hlg;
(9) ETBR;
(10) MSG783;
(11) STEAP2;
(12) TrpM4;
(13) CRIPTO;
(14) CD21;
(15) CD79b;
(16) FcRH2;
(17) HER2;
(18) NCA;
(19) MDP;
(20) IL20R-alpha;
(21) Brevican;
(22) EphB2R;
(23) ASLG659;
(24) PSCA;
(25) GEDA;
(26) BAFF-R;
(27) CD22;
(28) CD79a;
(29) CXCR5;
(30) HLA-DOB;
(31) P2X5;
(32) CD72;
(33) LY64;
(34) FcRH1;
(35) IRTA2;
(36) TENB2;
(37) PSMA—FOLH1;
(38) SST;
(38.1) SSTR2;
(38.2) SSTR5;
(38.3) SSTR1;
(38.4) SSTR3;
(38.5) SSTR4;
(39) ITGAV;
(40) ITGB6;
(41) CEACAM5;
(42) MET;
(43) MUC1;
(44) CA9;
(45) EGFRvIII;
(46) CD33;
(47) CD19;
(48) IL2RA;
(49) AXL;
(50) CD30—TNFRSF8;
(51) BCMA—TNFRSF17;
(52) CT Ags—CTA;
(53) CD174 (Lewis Y)—FUT3;
(54) CLEC14A;
(55) GRP78—HSPA5;
(56) CD70;
(57) Stem Cell specific antigens;
(58) ASG-5;
(59) ENPP3;
(60) PRR4;
(61) GCC—GUCY2C;
(62) Liv-1—SLC39A6;
(63) 5T4;
(64) CD56—NCMA1;
(65) CanAg;
(66) FOLR1;
(67) GPNMB;
(68) TIM-1—HAVCR1;
(69) RG-1/Prostate tumor target Mindin—Mindin/RG-1;
(70) B7-H4—VTCN1;
(71) PTK7;
(72) CD37;
(73) CD138—SDC1;
(74) CD74;
(75) Claudins—CLs;
(76) EGFR;
(77) Her3;
(78) RON—MST1R;
(79) EPHA2;
(80) CD20—MS4A1;
(81) Tenascin C—TNC;
(82) FAP;
(83) DKK-1;
(84) CD52;
(85) CS1—SLAMF7;
(86) Endoglin—ENG;
(87) Annexin A1—ANXA1;
(88) V-CAM (CD106)—VCAM1.

### Claim 6 (depends on 2)

The conjugate of claim 2 wherein the antibody or antibody fragment is a cysteine-engineered antibody.

### Claim 7 (depends on 2)

The conjugate according to claim 2 wherein the drug loading (p) of drugs (D) to antibody (Ab) is an integer from 1 to about 8.

### Claim 8 (depends on 7)

The conjugate according to claim 7, wherein p is 1, 2, 3, or 4.

### Claim 9 (depends on 2)

A composition comprising a mixture of the drug conjugate compounds according to claim 2, wherein the average drug loading per antibody in the mixture of antibody-drug conjugate compounds is about 1 to about 8.

### Claim at position 10

-12. (canceled)

### Claim 13 (depends on 2, 9)

A pharmaceutical composition comprising the conjugate according to claim 2 or composition according to claim 9 and a pharmaceutically acceptable diluent, carrier or excipient.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13 further comprising a therapeutically effective amount of a chemotherapeutic agent.

### Claim 15

(canceled)

### Claim 16 (depends on 13)

A method of treating cancer comprising administering to a patient the pharmaceutical composition of claim 13.

### Claim 17 (depends on 16)

The method of claim 16 wherein the patient is administered a chemotherapeutic agent, in combination with the conjugate.

### Claim 18 (depends on 2)

A method of preparing a conjugate according to claim 2, the method comprising the step of reacting a cell binding agent with
